Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome

< Back to All Resources

A new study published in The New England Journal of Medicine found that buprenorphine may be more effective than morphine for the treatment of neonatal abstinence syndrome (NAS). Infants with NAS treated with sublingual buprenorphine had a shorter duration of treatment and shorter hospital stay than infants treated with oral morphine.


Related Topics

  • Behavioral Health
  • Medications for Addiction Treatment (MAT)
  • Medical Care
  • Neonatal Abstinence Syndrome (NAS)